Booster study of Infanrix hexa in toddlers previously primed with investigational or licensed hexavalent vaccine

Phase 2, open-label trial of pertussis filamentous haemagglutinin in Preventable infectious diseases (VPD) (3 arms), sponsored by GSK. Primary endpoints: Persistence of antibodies at the time of booster vaccination in investigationally primed groups, Persistence of antibodies at the time of booster vaccination in licensed vaccine-primed group and 2 more. Started Dec 2007; status: completed.